Pediatric papillary thyroid cancer: current management challenges

Frederik A Verburg1, Hanneke M Van Santen2, Markus Luster1

  • 1University Hospital Gießen and Marburg, Department of Nuclear Medicine, Marburg, Germany.

Oncotargets and Therapy
|January 19, 2017
PubMed

Insights

Pediatric differentiated thyroid cancer (DTC) is rare but increasing. This review covers diagnosis, surgery, and therapies for pediatric papillary thyroid cancer (PTC), highlighting management controversies and challenges.

Area of Science:

  • Pediatric Oncology
  • Endocrinology

Background:

  • Differentiated thyroid cancer (DTC) is rare in children and adolescents, accounting for ~1.4% of pediatric malignancies, but its incidence is rising.
  • Limited evidence exists for optimal treatment due to rarity and long patient survival, leading to numerous controversies in pediatric DTC management.

Approach:

  • This review provides an overview of challenging areas in patient and disease management for pediatric papillary thyroid cancer (PTC).
  • It discusses current data on diagnosis, surgical approaches, radionuclide therapy, and endocrine management.

Key Points:

  • Key areas of controversy in pediatric PTC include diagnostic strategies, surgical extent, and the roles of radioactive iodine and long-term hormone suppression.
  • Addressing these controversies is crucial for optimizing outcomes in this rare pediatric malignancy.

Conclusions:

  • Optimal management strategies for pediatric PTC remain debated, necessitating further research and evidence-based guidelines.
  • This review highlights critical areas requiring attention to improve the care and long-term outcomes for children and adolescents with PTC.